24.49
price down icon3.16%   -0.80
pre-market  Pre-market:  25.40   0.91   +3.72%
loading
Beam Therapeutics Inc stock is traded at $24.49, with a volume of 838.78K. It is down -3.16% in the last 24 hours and up +3.55% over the past month. Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$25.29
Open:
$25.25
24h Volume:
838.78K
Relative Volume:
0.92
Market Cap:
$2.03B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-5.4302
EPS:
-4.51
Net Cash Flow:
$-153.40M
1W Performance:
-10.95%
1M Performance:
+3.55%
6M Performance:
-1.41%
1Y Performance:
-20.38%
1-Day Range:
Value
$24.39
$25.87
1-Week Range:
Value
$23.62
$27.82
52-Week Range:
Value
$20.84
$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
374
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BEAM 24.49 2.03B 352.57M -143.01M -153.40M -4.51
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
Nov 19, 2024

Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR

Nov 19, 2024
pulisher
Nov 16, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™

Nov 11, 2024
pulisher
Nov 10, 2024

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 09, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Beam Therapeutics president sells $1.35 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 08, 2024

Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN

Nov 07, 2024
pulisher
Nov 06, 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Beam points to positive data with key base editing asset - pharmaphorum

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 05, 2024

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s early base editing clinical data overshadowed by patient death - The Business Journals

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics to Present Data Across Hematology - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Posts Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Nov 05, 2024

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):